Insulin Biosimilar MarketThe global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year ...

Picture this: You're packing up your office, getting ready to head home for the evening, when your human resources manager peaks her head in. She explains that she has just fielded a complaint ...

While all five FTC commissioners voted to issue the Report, both Republican commissioners also issued separate statements expressing concerns about specific aspects of the Report. In a separately ...

In last week’s question about burning out doing work that you love, I wrote this: I used to think the cure for burn-out was lots of downtime and relaxation — and sometimes it is — but what’s worked ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Thankfully, in 2021, the Food and Drug Administration (FDA) approved the first biosimilar form of insulin (Semglee), paving the way for cost-effective alternatives to brands such as Lantus. Why You ...

Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...